News
RVPHW
0.0645
+3.70%
0.0023
Weekly Report: what happened at RVPHW last week (0421-0425)?
Weekly Report · 6d ago
Weekly Report: what happened at RVPHW last week (0414-0418)?
Weekly Report · 04/21 09:42
Weekly Report: what happened at RVPHW last week (0407-0411)?
Weekly Report · 04/14 09:39
REVIVA PHARMACEUTICALS HOLDINGS INC <RVPH.O>: BENCHMARK CUTS TARGET PRICE TO $14 FROM $17
Reuters · 04/09 11:29
Weekly Report: what happened at RVPHW last week (0331-0404)?
Weekly Report · 04/07 09:39
REVIVA PHARMACEUTICALS: EXPECTS TO REPORT MATERIAL WEAKNESSES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
Reuters · 03/31 21:18
REVIVA PHARMACEUTICALS HOLDINGS FILES FOR NON-TIMELY 10-K - SEC FILING
Reuters · 03/31 21:18
BRIEF-Reviva Pharmaceuticals FY EPS USD -0.9
Reuters · 03/31 20:06
REVIVA REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
Reuters · 03/31 20:05
Weekly Report: what happened at RVPHW last week (0324-0328)?
Weekly Report · 03/31 09:42
Weekly Report: what happened at RVPHW last week (0317-0321)?
Weekly Report · 03/24 09:38
Weekly Report: what happened at RVPHW last week (0310-0314)?
Weekly Report · 03/17 09:41
Weekly Report: what happened at RVPHW last week (0303-0307)?
Weekly Report · 03/10 09:42
Weekly Report: what happened at RVPHW last week (0224-0228)?
Weekly Report · 03/03 09:42
Weekly Report: what happened at RVPHW last week (0217-0221)?
Weekly Report · 02/24 09:42
Weekly Report: what happened at RVPHW last week (0210-0214)?
Weekly Report · 02/17 09:41
Weekly Report: what happened at RVPHW last week (0203-0207)?
Weekly Report · 02/10 09:39
Weekly Report: what happened at RVPHW last week (0127-0131)?
Weekly Report · 02/03 09:41
Weekly Report: what happened at RVPHW last week (0120-0124)?
Weekly Report · 01/27 09:42
REVIVA PHARMACEUTICALS HOLDINGS INC <RVPH.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $11 FROM $14
Reuters · 01/22 12:28
More
Webull provides a variety of real-time RVPHW stock news. You can receive the latest news about Reviva Pharmaceutcls Hldgs Inc through multiple platforms. This information may help you make smarter investment decisions.
About RVPHW
More
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).